This week: the China National Medical Products Administration has approved Yescarta® as the first CAR-T therapy in the country, the US FDA has authorized a Phase II trial to assess the efficacy and safety of multiple intravenous infusions of allogeneic adipose-derived mesenchymal stem cells in people with Parkinson’s disease, CellPoint has entered into a strategic collaboration with Lonza to deliver CAR-T cells to patients at point-of-care, and a new CAR-T company has been launched to develop therapies for immuno-oncology and autoimmune diseases. The news highlights: Yescarta® becomes the first CAR-T therapy approved in China US FDA authorizes simultaneous stem cell…